Endotoxin and adjunctive therapies in gram-negative sepsis

Seminars in Pediatric Infectious Diseases

Volumn 12, Issue 1, 2001, Pages 17-23

  Romano, Michael J ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIBODY; CD14 ANTIGEN; DT 5461; E 5531; ENDOTOXIN ANTIBODY; L 161240; LIPID A; LIPID A DERIVATIVE; LIPID X; LIPOPOLYSACCHARIDE BINDING PROTEIN; MONOCLONAL ANTIBODY; NEUPRAX; POLYMYXIN B; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG PROTEIN BINDING; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MENINGOCOCCEMIA; PHASE 3 CLINICAL TRIAL; REVIEW; SEPSIS; SEPTICEMIA;

EID: 0035137843     PISSN: 10451870     EISSN: None     Source Type: Journal    
DOI: 10.1053/spid.2001.19231     Document Type: Article

References (100)

1. Has the mortality of septic shock changed with time?
2. Endotoxemia in human septic shock
3. Hemodynamic responses to gram-positive versus gram-negative sepsis in critically ill patients with and without circulatory shock
4. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways
5. Lipopolysaccharide recognition, CD 14, and lipopolysaccharide receptors
6. LPS-binding proteins and receptors
7. Endotoxin interactions with lipopolysaccharide-responsive cells
8. CD-14 deficient mice are exquisitely insensitive to the effects of LPS
9. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD-14 deficient mice
10. Anti-CD14 monoclonal antibodies inhibit the production of tumor necrosis factor alpha and interleukin-10 by human monocytes stimulated with killed and live Haemophilus influenzae or Streptococcus pneumoniae organisms
11. Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin
12. A region of human CD 14 required for lipopolysaccharide binding
13. Recombinant soluble CD 14 mediates the activation of endothelial cells by lipopolysaccharide
14. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14
15. Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS
16. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum
17. Biosynthesis of lipopolysaccharide binding protein in rabbit hepatocytes
18. Lipopolysaccharide binding protein expression in primary human hepatocytes and Hep G2 hepatoma cells
19. Molecular cloning, characterization, and tissue distribution of rat lipopolysaccharide binding protein. Evidence for extrahepatic expression
20. Induction of lipopolysaccharide-binding protein gene expression in cultured rat pulmonary artery smooth muscle cells by interleukin 1 beta
21. Lipopolysaccharide binding protein-mediated complexation of llpopolysaccharide with soluble CD14
22. Targeted deletion of the LBP gene leads to profound suppression of LPS responses ex vivo while in vivo responses remain intact
23. Lipopolysaccharide (LPS) binding protein catalyzes binding of LPS to lipoproteins
24. Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein
25. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria
26. Dual effects of soluble CD14 on LPS priming of neutrophils
27. Protection against lethality of E. coli endotoxin with "O" antiserum
28. Immunization with R mutants of Salmonella minnesota: II. Serological response to lipid A and the lipopolysaccharide of Re mutants
29. Treatment of gramnegative bacteremia and shock with human antiserum to a mutant Escherichia coli
30. The biosynthesis of cell wall lipopolysaccharide in Escherichia coli: I. The biochemical properties of a uridine diphosphate galactose 4-epimeraseless mutant
31. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, gram-negative infections in patients with prolonged neutropenia
32. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid
33. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: A prospective double-blind study
34. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial
35. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies
36. Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients
37. Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial
38. Treatment of septic shock with human monoclonal antibody HA- 1A
39. The French National Registry of HA-1A (Centoxin) in septic shock
40. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis
41. A second large, controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial
42. O2-independent killing of gram-negative bacteria by intact granulocytes. The role of a potent bactericidal membrane-perturbing protein
43. The bactericidal/permeability-increasing protein (BPI) is present in specific granules of human eosinophils
44. Bactericidal/permeability-increasing protein, a lipopolysaccharide-specific protein on the surface of human peripheral blood monocytes
45. 2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria
46. Bactericidal/permeability-increasing protein inhibits growth of a strain of Acholeplasma laidlawii and L forms of the gram-positive bacteria Staphylococcus aureus and Streptococcus pyogenes
47. 23)
48. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein
49. Serogroup B meningococcal disease: Oregon, 1994
50. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992: Emergence of a virulent clone of Neisseira meningitidis
51. Epidemic serogroup B meningococcal disease in Oregon: The evolving epidemiology of the ET-5 strain
52. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease
53. Meningococcal infections in children: A review of 100 cases
54. Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987
55. Epidemiology of meningococcal infections in children in mid-southern part of Turkey
56. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis
57. 21) as adjunctive treatment for children with severe meningococcal sepsis: A randomized trial
58. 21) in patients with hemorrhage due to trauma: Results of a multicenter phase II clinical trial
59. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Re chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia
60. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis
61. Vaccines and antibodies in the prevention and treatment of sepsis
62. Antibodies against CD14 protect primates from endotoxin-induced shock
63. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin
64. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood
65. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide)
66. In vivo protection against endotoxin by plasma high density lipoprotein
67. Role for circulating lipoproteins in protection from endotoxin toxicity
68. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia
69. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia
70. Endotoxin-induced intravascular coagulation: Prevention with polymyxin B sulphate
71. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides
72. Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: Designing and antiendotoxin efficacy in the clinical application
73. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber
74. Effects of hemoperfusion with polymyxin B-immobilized fibre on serum neopterin and soluble interleukin-2 receptor concentrations in patients with septic shock
75. Hemoperfusion with polymyxin B-immobilized fiber attenuates the increased plasma levels of thrombomodulin and von Willebrand factor from patients with septic shock
76. Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: Decrease in plasma levels of soluble P-selectin, platelet factor 4 and beta-thromboglobulin
77. Lipid X protects mice against fatal Escherichia coli infection
78. Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin
79. Synthesis and biological evaluation of carbocyclic analogues of lipid X: New nonpolar antagonists of LPS induced TNF production
80. Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits
81. Antitumor effect of DT-5461, a lipid A derivative, against human tumor xenografts is mediated by intratumoral production of tumor necrosis factor and affected by host immunosuppressive factors in nude mice
82. A novel synthetic lipid A analog with low endotoxicity, DT- 4561, prevents lethal endotoxemia
83. E5531, a pure endotoxin antagonist of high potency
84. E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide
85. Regulation of UDP-3-O-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase in Escherichia coli. The second enzymatic step of lipid A biosynthesis
86. The lipid A biosynthesis mutation 1pxA2 of Escherichia coli results in drastic antibiotic supersusceptibility
87. Antibacterial agents that inhibit lipid A biosynthesis
88. Anti-endotoxin monoclonal antibodies
89. Reflecting and regrouping after failed trials, sepsis researchers forge on
90. Antibodies to core lipopolysaccharide determinants: Absence of cross-reactivity with heterologous lipopolysaccharides
91. st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL
92. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide
93. Endotoxin versus bacteremia: A comparison focusing on clinical relevance
94. Tissue tumor necrosis factor mRNA expression following cecal ligation and puncture or intraperitoneal injection of endotoxin
95. Comparison of the induction of endotoxin tolerance in endotoxemia and peritonitis by monophosphoryl lipid A and lipopolysaccharide
96. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome)